Kilitch Drugs (India) (NSE:KILITCH) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
84 GF Score
Price ₹183.59
GF Value ₹227.52
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Kilitch Drugs (India) Quality Rank Related Terms

NSE:KILITCH
84GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹183.59 is trading 19.3% below its estimated GF Value™ of ₹227.52. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Quality Rank:
  • GF Value™: ₹227.52 vs. price of ₹183.59 (19.3% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
84GF Score

Get the complete analysis for NSE:KILITCH

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹183.59
Price
₹227.52
GF Value